Vizz being approved by the FDA marks a step in the right direction for treating vision loss in an accessible way.

Lenz Therapeutics has received approval from the Food and Drug Administration for Vizz (aceclidine ophthalmic solution) 1.44% ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

It is anticipated that Vizz, manufactured by Lenz Therapeutics, will become commercially available in the US by the end of ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful.

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.